Medicamentos para prevenir las cefaleas migrañosas en ... - marchioli

Medicamentos para prevenir las cefaleas migrañosas en los niños
Characteristics of included studies
Participants
Interventions
Outcomes
Notes
Allocation concealment
Study
Methods
Participants
Interventions
Outcomes
Notes
Allocation concealment
53 randomised. 14 withdrawals.
Groups A (22 patients) and B (17) were poorly comparable.
21/39 males. Age range: 9 to 15 years.
A: 4-week placebo, then propranolol 40 mg twice daily for 6 weeks, then optional
increase to thrice daily for 6 weeks, then 2-week washout, placebo twice daily for 6
weeks, then optional increase to thrice daily for 6 weeks.
B: 4-week placebo, then placebo twice daily for 6 weeks, then optional increase to
thrice daily for 6 weeks, then 2-week washout, then propranolol 40 mg twice daily for
6 weeks, then optional increase to thrice daily for 6 weeks.
Frequency, average duration, headache severity score, and symptomatic treatment.
Non-parametric data which could not be further analysed. Investigators reported no
benefit with propranolol. Adverse event of increase in headache duration noted.
14 withdrawals. 4 - outside age range, 8 - did not comply with treatment, 2 - failed to
complete.
Adverse events: Propranolol: 3 - increased appetite; 2 - abdominal pain; 2 - worsening;
2 - amenorrhoea; 2 - weight gain; 1 - anorexia; 1 - menorrhagia.
Headache severity score =
(1 x number of mild headaches + 2 x number of moderate headaches + 3 x number of
severe headaches)/total number of headaches.
B
Gillies 1986
Randomised, double-blind, placebo-controlled, crossover.
Randomisation not described. Active and control identical.
Migraine defined as a periodic headache with at least three of the following features:
aura, nausea and vomiting, and positive family history.
Symptomatic treatment and compliance not reported.
47 randomised. 8 withdrawals.
Groups A (16 patients) and B (23 patients) were comparable for sex, headache type,
and frequency.
27/39 males. Age range: 7 to 14 years.
A: Pizotifen 0.5 mg twice daily for 6 weeks, then thrice daily for 6 weeks, then placebo
twice daily for 6 weeks, then thrice daily for 6 weeks.
B: Placebo twice daily for 6 weeks, then thrice daily for 6 weeks, then pizotifen 0.5 mg
twice daily for 6 weeks, then thrice daily for 6 weeks.
Number of attacks, total duration of attacks, duration of longest attack, and mean
duration of attacks.
Non-parametric data which could not be further analysed. Investigators reported no
significant benefit from pizotifen.
8 excluded. 6 failed to attend; 2 had spontaneous
remission.
No standardised variability data thus preventing analysis.
17% had adverse events. 4 on active and 3 on placebo. 1 had excessive weight gain
on pizotifen.
B
Página 22
Copyright © John Wiley & Sons Ltd. Usado con permiso de John Wiley & Sons, Ltd.